NCT06384469

Brief Summary

This is a prospective observation cohort investigation. Patients, that is participants, undergoing primary functional rhinoplasty will be evaluated in terms of measuring capillary blood lactic acid concentration in the nasal skin-soft tissue envelope immediately after the procedure and 7 days after the procedure. The aim of our study is to test whether or not different rhinoplasty approaches and volume of the used autologous cartilage grafts impact the nasal skin-soft tissue metabolism.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
4mo left

Started Jan 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress81%
Jan 2025Sep 2026

First Submitted

Initial submission to the registry

April 22, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 25, 2024

Completed
8 months until next milestone

Study Start

First participant enrolled

January 2, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 2, 2026

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Expected
Last Updated

April 29, 2024

Status Verified

April 1, 2024

Enrollment Period

1 year

First QC Date

April 22, 2024

Last Update Submit

April 25, 2024

Conditions

Keywords

Open rhinoplasty approachClosed rhinoplasty approachLactic acidSkin-soft tissue envelopeMetabolismAutologous cartilage grafting

Outcome Measures

Primary Outcomes (2)

  • Difference of capillary blood lactic acid concentration in the nasal skin-soft tissue envelope depending on the rhinoplasty approach

    In participants undergoing primary functional rhinoplasty, the capillary blood lactic acid concentration from the skin-soft tissue envelope will be assessed by using Statstrip lactate measuring device and Statstrip test strips immediately after the procedure and 7 days after the procedure.

    immediately after the surgical procedure and 7 days after the procedure

  • Correlation between the used autologous cartilage graft volume and lactic acid concentration in the nasal skin-soft tissue envelope

    In the same participants undergoing different rhinoplasty approach, the volume of the used autologous cartilage grafts will be measured by using water displacement method, and this result will be correlated with the capillary blood lactic acid concentration from the skin-soft tissue envelope.

    immediately after the surgical procedure and 7 days after the procedure

Study Arms (2)

Patients undergoing open rhinoplasty approach

Patients undergoing open rhinoplasty approach, of which most of will be augmented by using autologous cartilage grafts.

Patients undergoing closed approach rhinoplasty.

Patients undergoing closed approach rhinoplasty of which only few will be augmented by using autologous cartilage grafts.

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients between 18 and 80 years of age, scheduled for primary functional rhinoplasty, who are willing to comply with the study and sign the informed consent, previously approved by the ethics commitee.

You may qualify if:

  • Adult patients undergoing primary functional rhinoplasty who comply with the study
  • Adult patients undergoing primary functional rhinoplasty who have singed the informed consent, previously approved by the ethics commitee.

You may not qualify if:

  • patients with previous surgical procedures to the nose
  • patients with greater previous injury or burns to the nasal skin
  • patients with autoimmune skin conditions
  • patients with significant cardiovascular diseases
  • patients unwilling to comply with the study
  • patients who do not want to sign the informed consent, previously approved by the ethics commitee.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Marko Velimir Grgić, MD, PhD

    UHC Sestre milosrdnice

    STUDY CHAIR

Central Study Contacts

Marko Velimir Grgić, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
medical doctor, resident

Study Record Dates

First Submitted

April 22, 2024

First Posted

April 25, 2024

Study Start

January 2, 2025

Primary Completion

January 2, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

April 29, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Individual participant data are not to be shared with other researchers.